Traumatic brain injury has faced numerous challenges in drug development, primarily due to
the difficulty of effectively delivering drugs to the brain. However, there is a potential solution …

Drug targeting to inflammatory brain pathologies such as stroke and traumatic brain injury
remains an elusive goal. Using a mouse model of acute brain inflammation induced by local …

Traumatic brain injury (TBI) is known to alter the structure and function of the blood–brain
barrier (BBB). Blunt force or explosive blast impacting the brain can cause neurological …

The endothelium is a thin monolayer of specialized cells that lines the luminal wall of blood
vessels and constitutes the critical innermost portion of the physical barrier between the …

Severe traumatic brain injury (TBI), such as that suffered by patients with cerebral contusion,
is a major cause of death and disability in young persons. Effective therapeutics to treat or …

After more than 100 failed drug trials for acute ischemic stroke (AIS), one of the most
commonly cited reasons for the failure has been that drugs achieve very low concentrations …

The current lack of understanding about how nanocarriers cross the blood‐brain barrier
(BBB) in the healthy and injured brain is hindering the clinical translation of nanoscale brain …

Effective delivery of mRNA or small molecule drugs to the brain is a significant challenge in
developing treatment for acute ischemic stroke (AIS). To address the problem, we have …

A major challenge for the efficient treatment of traumatic brain injury is the need for
therapeutic molecules to cross the blood-brain barrier to enter and accumulate in brain …

Traumatic brain injury (TBI) is one of the main causes of disability in children and young
adults, as well as a significant concern for elderly individuals. Depending on the severity, TBI …